Vera Therapeutics VERA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $114.35M+108% | $354.73M+283% | $57.77M+112% | $49.12M+95.8% | $55.09M-20.3% | ||
| $482.41M-9.8% | $359.86M-34.4% | $439.62M+34.8% | $507.71M+41.3% | $534.74M+59.8% | ||
| $615.8M+1.6% | $728.88M+11.9% | $511.31M+40.4% | $571.35M+44.7% | $606.08M+45.6% | ||
| $621.74M+1.9% | $734.73M+12.1% | $517.5M+40.4% | $578.53M+45.6% | $610.17M+45.5% | ||
| $66.91M+155% | $62.27M+181% | $48.03M+87.7% | $34.69M+4.2% | $26.19M-37.5% | ||
| $45.15M+106% | $53.46M+111% | $41.88M+58.3% | $33.55M+82.2% | $21.89M+50.5% | ||
| $75.03M+47.4% | $74.84M+47.6% | $74.65M+47.9% | $74.46M+48.1% | $50.91M+1.7% | ||
| $122.04M+62.4% | $130.21M+65.8% | $118.62M+49.2% | $110.25M+58.8% | $75.17M+14.2% | ||
| $72K+12.5% | $71K+10.9% | $64K+16.4% | $64K— | $64K— | ||
| -$881.9M-71.9% | -$760.87M-65.0% | -$669.77M-60.3% | -$589.48M-58.8% | -$512.94M-52.0% | ||
| $499.7M-6.6% | $604.52M+4.7% | $398.88M+38.0% | $468.28M+42.8% | $535M+51.3% | ||
| $621.74M+1.9% | $734.73M+12.1% | $517.5M+40.4% | $578.53M+45.6% | $610.17M+45.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vera Therapeutics's total assets?
- Vera Therapeutics (VERA) holds $621.7M in total assets, up 1.9% year over year.
- How much debt does Vera Therapeutics have?
- Vera Therapeutics carries $75.0M in total debt against $499.7M of shareholders' equity, a debt-to-equity ratio of 0.15.
- How much cash does Vera Therapeutics have?
- Vera Therapeutics holds $114.4M in cash and equivalents.
- Can Vera Therapeutics cover its short-term obligations?
- Its current ratio is 13.64 — current assets exceed current liabilities.
- Where does Vera Therapeutics's balance sheet data come from?
- Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.